August 23, 2018 04:33 PM EDT
People
Pharma

Sang­amo re­searcher charged with in­sid­er trad­ing in lat­est round of SEC ac­cu­sa­tions lev­eled at a biotech ex­ec

John Carroll

Editor & Founder

Back in ear­ly 2014, in­vestors in Sang­amo reaped some quick gains when Bio­gen an­nounced that it had just struck a deal with the gene edit­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Lil­ly’s oral SERD makes strides in breast can­cer with Phase 3 da­ta

The End­points 100: The biotech in­dus­try braces for Trump 2.0

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

Ace­lyrin says good­bye to the drug that got it a $540M IPO in 2023

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times